NeuroMetrix, Inc.

Equities

NURO

US6412558800

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 02:00:00 17/07/2024 am IST			5-day change	1st Jan Change
3.71 ^USD	+0.54%		+1.64%	+3.06%

15/05	NeuroMetrix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
19/04	Sector Update: Health Care Stocks Advance Late Afternoon	MT

Neurometrix, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2019

January 27, 2020 at 05:59 pm IST

NeuroMetrix, Inc. announced earnings results for the fourth quarter ended December 31, 2019. For the fourth quarter, the company announced sales was USD 1.706 million compared to USD 3.728 million a year ago. Operating loss was USD 1.658 million compared to USD 2.821 million a year ago. Net loss was USD 1.056 million compared to USD 2.802 million a year ago. For the full year, sales was USD 9.272 million compared to USD 16.090 million a year ago. Operating loss was USD 11.534 million compared to USD 12.291 million a year ago. Net loss was USD 3.773 million compared to net income of USD 23,605 a year ago.

Latest news about NeuroMetrix, Inc.

NeuroMetrix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05	CI
Sector Update: Health Care Stocks Advance Late Afternoon	20/04	MT
Sector Update: Health Care Stocks Rise Friday Afternoon	19/04	MT
NeuroMetrix Says Joshua Horowitz Joining Board, Terminates At-the-Market Equity Facility	19/04	MT
Neurometrix, Inc. Appoints Joshua S. Horowitz as a Class III director on the Board	19/04	CI
NeuroMetrix, Inc. Announces Publication of Study Demonstrating That DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy	14/03	CI
Ephraim Fields Discloses his Views on NeuroMetrix	28/02	CI
RS Fund Discloses its Views on NeuroMetrix	27/02	CI
Transcript : NeuroMetrix, Inc., Q4 2023 Earnings Call, Feb 22, 2024	22/02
NeuroMetrix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/02	CI
NeuroMetrix, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	22/02	CI
NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder Value	13/02	CI
Neurometrix, Inc. Reports Encouraging Results from Pilot Clinical Trial of Quell®? in Post-Acute Covid-19 Syndrome (Long Covid)	12/12	CI
NeuroMetrix, Inc. Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy	05/12	CI
Sector Update: Health Care Stocks Advance in Late Afternoon Trading	21/11	MT
Sector Update: Health Care Stocks Advance in Afternoon Trading	21/11	MT
NeuroMetrix Announces 1-for-8 Reverse Stock Split; Shares Fall	20/11	MT
Transcript : NeuroMetrix, Inc., Q3 2023 Earnings Call, Oct 26, 2023	26/23/26
NeuroMetrix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	26/23/26	CI
North American Morning Briefing : Nasdaq Futures -2-	26/23/26	DJ
NeuroMetrix, Inc. and the National Fibromyalgia Association to Collaborate to Improve the Quality of Life for People Living with Fibromyalgia	02/23/02	CI
Transcript : NeuroMetrix, Inc., Q2 2023 Earnings Call, Jul 27, 2023	27/23/27
NeuroMetrix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	27/23/27	CI
North American Morning Briefing : Nasdaq Futures -2-	20/23/20	DJ
NeuroMetrix, Inc. Announces Sales Force Expansion for Quell Fibromyalgia	11/23/11	CI

Chart NeuroMetrix, Inc.

Duration

Period

More charts

Company Profile

NeuroMetrix, Inc. is a commercial-stage healthcare company that develops and commercializes neurotechnology devices to address unmet needs in the chronic pain and diabetes markets. The Company's products are wearable or hand-held medical devices enabled by proprietary consumables and software solutions that include mobile apps, enterprise software and cloud-based systems. The Company has two commercial brands. Quell is a wearable neuromodulation platform. DPNCheck is a point-of-care screening test for peripheral neuropathy. It operates two product categories: Diagnostic technology and Therapeutic technology. Diagnostic technology product category is engaged in point-of-care peripheral neuropathy assessment. Therapeutic technology product category is engaged in wearable neuromodulation for chronic pain syndromes. Its patients control and personalize the technology via a mobile phone application, and their utilization and certain clinical metrics may be tracked in the Quell Health Cloud.

Sector

Medical Equipment, Supplies & Distribution

Calendar

18/07/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
NEUROMETRIX, INC.	+3.06%	7.46M
ABBOTT LABORATORIES	-6.68%	179B
MEDTRONIC PLC	-5.20%	100B
BECTON, DICKINSON AND COMPANY	-5.38%	66.67B
HOYA CORPORATION	+18.27%	44.81B
DEXCOM, INC.	-6.47%	46.16B
CENCORA, INC.	+9.74%	44.38B
METTLER-TOLEDO INTERNATIONAL, INC.	+14.01%	29.53B
TERUMO CORPORATION	+21.29%	25.83B
WEST PHARMACEUTICAL SERVICES, INC.	-6.53%	23.97B

Other Medical Equipment, Supplies & Distribution